Inogen (NASDAQ:INGN) Upgraded at StockNews.com

Inogen (NASDAQ:INGN) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a research report issued to clients and investors on Tuesday.

Separately, Needham & Company LLC restated a “hold” rating on shares of Inogen in a report on Friday, November 8th.

Inogen Price Performance

INGN opened at $10.33 on Tuesday. Inogen has a fifty-two week low of $4.93 and a fifty-two week high of $13.33. The firm has a market capitalization of $246.06 million, a PE ratio of -4.59 and a beta of 1.04. The company’s 50-day moving average is $9.88 and its 200 day moving average is $9.49.

Institutional Investors Weigh In On Inogen

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Divisadero Street Capital Management LP increased its position in shares of Inogen by 682.3% during the second quarter. Divisadero Street Capital Management LP now owns 2,346,766 shares of the medical technology company’s stock valued at $19,079,000 after acquiring an additional 2,046,766 shares during the last quarter. Brown Capital Management LLC increased its position in shares of Inogen by 26.6% during the 1st quarter. Brown Capital Management LLC now owns 1,975,312 shares of the medical technology company’s stock valued at $15,941,000 after purchasing an additional 414,903 shares during the last quarter. Vanguard Group Inc. raised its stake in shares of Inogen by 4.9% during the 1st quarter. Vanguard Group Inc. now owns 1,424,026 shares of the medical technology company’s stock worth $11,492,000 after purchasing an additional 65,954 shares during the period. AQR Capital Management LLC boosted its holdings in shares of Inogen by 29.3% in the 2nd quarter. AQR Capital Management LLC now owns 570,994 shares of the medical technology company’s stock worth $4,642,000 after buying an additional 129,307 shares during the last quarter. Finally, Meros Investment Management LP grew its position in Inogen by 1.6% during the second quarter. Meros Investment Management LP now owns 397,209 shares of the medical technology company’s stock valued at $3,229,000 after buying an additional 6,385 shares during the period. Hedge funds and other institutional investors own 89.94% of the company’s stock.

About Inogen

Inogen, Inc, a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.